Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling

ABSTRACT Aficamten is a next‐in‐class, cardiac myosin inhibitor in development as a potential chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PK) model was developed using data from nine clinical studies to characterize aficamten PK and ident...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Donghong Xu, Hanbin Li, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Polina German, Justin Lutz
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-12-01
Serie:	CPT: Pharmacometrics & Systems Pharmacology
Soggetti:	cardiovascular disease clinical trials inhibitors modeling population pharmacokinetics simulation
Accesso online:	https://doi.org/10.1002/psp4.70099
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!